Monitoring of adverse events after immunization against a new coronavirus infection among young people

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: To increase public confidence in vaccine prevention and to actually assess the safety of vaccines against COVID-19, it is necessary to study the frequency and structure of adverse events after immunization in the post-registration period of vaccine use.

AIM: To assess the frequency and structure of adverse events after immunization against COVID-19 among young people during the period of post-registration use of vaccines.

MATERIALS AND METHODS: A single center cross-sectional study was conducted based on a questioning of 333 respondents aged 18–25 years (76.88% female, 23.12% male). The questionnaire included 2 groups of questions: general and special (nature of post-vaccination reactions, history of COVID-19 disease before and after vaccination). Statistical processing of the results was carried out using standard Microsoft Office Excel 2016 software packages.

RESULTS: The most common complaints after vaccination were soreness at the injection site (57.66%), weakness (54.65%) and body aches (24.92%). There were local and general/combined (weak, moderate, strong) reactions, they were observed in 30.93% of respondents after 1 dose and 45.35% after 2 doses. In the structure of reactions after the first immunization, general weak reactions (15.32%, p=0.001) were significantly more common than others, after the second — local ones (21.92%, p <0.0001). A strong correlation was established between responses to the 1st and 2nd doses of the vaccine (r=0.94, p <0.0001). When studying the frequency and structure of post-vaccination reactions in sex groups and in those who had COVID-19 before vaccination and those who did not, no significant differences were found.

CONCLUSIONS: The study found that among young people, the majority did not have objective reactions after immunization against a new coronavirus infection. General weak and local reactions were more common among the objective post-vaccination reactions.

About the authors

Nataliya V. Gabbasova

Voronezh State Medical University named after N.N. Burdenko

Author for correspondence.
Email: natalia_gabb@mail.ru
ORCID iD: 0000-0001-5042-3739
SPIN-code: 6629-4401

MD, Dr. Sci. (Med.), Associate Professor

Russian Federation, Voronezh

Nikolay P. Mamchik

Voronezh State Medical University named after N.N. Burdenko

Email: mamchik1949@yandex.ru
ORCID iD: 0000-0002-6952-0018
SPIN-code: 7374-0575

MD, Dr. Sci. (Med.), Professor

Russian Federation, Voronezh

Liliya A. Yatsenko

Voronezh State Medical University named after N.N. Burdenko

Email: yatsenko.lili@yandex.ru
ORCID iD: 0000-0001-6095-4760
SPIN-code: 2075-3944

MD, Cand. Sci. (Med.)

Russian Federation, Voronezh

Olga L. Mazina

Voronezh State Medical University named after N.N. Burdenko

Email: olga_mazzina@mail.ru
ORCID iD: 0000-0003-3577-4439
SPIN-code: 7086-3528

MD, Cand. Sci. (Biol.)

Russian Federation, Voronezh

Victoria A. Knyazeva

Voronezh State Medical University named after N.N. Burdenko

Email: vic.knz@mail.ru
ORCID iD: 0000-0003-0247-5491
SPIN-code: 7705-3001

MD

Russian Federation, Voronezh

References

  1. Feldblium IV. Modern issues of vaccinal prevention. Preventive and Clinical Medicine. 2017;(2):20–27. (In Russ).
  2. Bogomiagkova ES. The attitude of Russians to vaccination against COVID-19: problems and contradictions. Problems of Social Hygiene, Public Health and the History of Medicine. 2021;29(S):736–742. (In Russ). doi: 10.32687/0869-866X-2021-29-s1-736-742
  3. Ryaguzova EV. Cognitive aspects of students’ attitudes towards COVID-19 Vaccination. Russian Psychological Journal. 2021;18(2):109–121. doi: 10.21702/rpj.2021.2.7
  4. Briko NI, Namazova-Baranova LS, Lobzin YuV, et al. Improving the Monitoring of Adverse Events Following Immunization (in Order of Discussion). Epidemiology and Vaccinal Prevention. 2016;15(6): 95–101. (In Russ). doi: 10.31631/2073-3046-2016-15-6-95-101
  5. Naygovzina NB, Khabriev RU, Krasheninnikov AE, Matveev AV. The organizational aspects of security support of participants of clinical testing of vaccine “Gam-COVID-Vac”. Problems of Social Hygiene, Public Health and the History of Medicine. 2021;29(1):5–13. (In Russ). doi: 10.32687/0869-866X-2021-29-1-5-13
  6. Yashina ER, Turzin PS, Lukichev KE, Ushakov IB. To the question of possible various manifestations after vaccination against a new coronavirus infection COVID-19. Hospital Medicine: Science and Practice. 2021;4(3):54–59. (In Russ).
  7. Zhogolev SD, Gorenchuk AN, Kuzin AA, et al. Evaluation of vaccine “Sputnik V” immunogenicity and reactogenicity when it is used in military personnel. Bulletin of the Russian Military Medical Academy. 2021;2(4):147–152. doi: 10.17816/brmma80760
  8. Dagan N, Barda N, Kepten E, et al.. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412–1423. doi: 10.1056/NEJMoa2101765
  9. Lutrick K, Ellingson KD, Baccam Z, et al. COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol. JMIR Res Protoc. 2021;10(6):e28925. doi: 10.2196/28925
  10. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854. doi: 10.1016/S0140-6736(20)31208-3
  11. Klugar M, Riad A, Mekhemar M, et al. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology (Basel). 2021;10(8):752. doi: 10.3390/biology10080752
  12. Wu Q, Dudley MZ, Chen X, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173. doi: 10.1186/s12916-021-02059-5
  13. Chu L, McPhee R, Huang W, et al.; mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39(20):2791–2799. doi: 10.1016/j.vaccine.2021.02.007
  14. Andrzejczak-Grządko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25(12):4418–4421. doi: 10.26355/eurrev_202106_26153
  15. Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93(7):4420–4429. doi: 10.1002/jmv.26996
  16. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. doi: 10.1136/bmj.n1088
  17. CDC COVID-19 Response Team; Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. doi: 10.15585/mmwr.mm7002e1
  18. Bolletta E, Iannetta D, Mastrofilippo V, et al. Uveitis and Other Ocular Complications Following COVID-19 Vaccination. J Clin Med. 2021;10(24):5960. doi: 10.3390/jcm10245960
  19. Hajjo R, Sabbah DA, Bardaweel SK, Tropsha A. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines (Basel). 2021;9(10):1186. doi: 10.3390/vaccines9101186
  20. Cantarelli Rodrigues T, Hidalgo PF, Skaf AY, Serfaty A. Subacromial-subdeltoid bursitis following COVID-19 vaccination: a case of shoulder injury related to vaccine administration (SIRVA). Skeletal Radiol. 2021;50(11):2293–2297. doi: 10.1007/s00256-021-03803-x
  21. Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two Cases of Graves’ Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid. 2021;31(9):1436–1439. doi: 10.1089/thy.2021.0142
  22. Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19. Vaccines (Basel). 2021;9(5):502. doi: 10.3390/vaccines9050502
  23. Sasikala M, Shashidhar J, Deepika G, et al. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. Int J Infect Dis. 2021;108:183–186. doi: 10.1016/j.ijid.2021.05.034
  24. Amit S, Beni SA, Biber A, et al. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg Infect Dis. 2021;27(4):1220–1222. doi: 10.3201/eid2704.210016
  25. Feldblyum IV. Epidemiological surveillance of vaccine prophylaxis. MediAl Journal. 2014;(3):37–55. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The structure of adverse events after immunization against a new coronavirus infection in young people aged 18–25 years.

Download (269KB)
Indexing metadata
3. Fig. 2. The structure of adverse events to 1 dose of vaccine against a new coronavirus infection in respondents who had been ill before vaccination and who had not recovered from COVID-19.

Download (273KB)
Indexing metadata

Copyright (c) 2021 Gabbasova N.V., Mamchik N.P., Yatsenko L.A., Mazina O.L., Knyazeva V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies